Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BAMBOOS HEALTH CARE HOLDINGS LIMITED

百本醫護控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2293)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The board of directors (the "Board" or the "Directors") of Bamboos Health Care Holdings Limited (the "Company") announces that on 29 April 2019 (the "Date of Grant"), the Board resolved to grant a total of 8,000,000 share options (the "Share Options") to 29 grantees of the Company (the "Grantees"), subject to acceptance of the Grantees and under the rules of the share option scheme adopted by the Company on 24 June 2014 (the "Share Option Scheme"), details of which can be found in the prospectus of the Company dated 30 June 2014. The Grantees are entitled, subject to the terms and conditions of grant and upon exercise, to subscribe for a total of 8,000,000 ordinary shares with nominal value of HK\$0.01 per share (the "Shares") in the share capital of the Company, representing 2% of the total 400,000,000 Shares in issue as at the Date of Grant.

Details of the Share Options are summarized as follows:

(i) Date of Grant 29 April 2019

(ii) Exercise price of Share HK\$1.44 per Share Options granted

(iii) Number of Share Options a total of 8,000,000 Share Options granted

(iv) Closing price of the Shares on the Date of Grant

HK\$1.44 per Share, which is the highest of: (i) the closing price of HK\$1.44 per Share as stated in the daily quotation sheet issued by the Stock Exchange on 29 April 2019, being the Date of Grant; (ii) the average closing price of HK\$1.38 per Share as stated in the daily quotation sheets issued by the Stock Exchange for five business days immediately preceding the Date of Grant; and (iii) HK\$0.01, being the nominal value of the Shares on the Date of Grant

(v) Validity period of the Share Options

The Share Options are valid for a period of 10 years commencing from the Date of Grant

(vi) Vesting schedule

The Company granted 3 types of Share Options with different vesting periods to the Grantees, details of which are as follows:

(i) Type 1 Share Options:

50% of the Share Options shall be vested from 30 April 2020 to 29 April 2029, both dates inclusive

50% of the Share Options shall be vested from 30 April 2021 to 29 April 2029, both dates inclusive

(ii) Type 2 Share Options:

40% of the Share Options shall be vested from 30 April 2020 to 29 April 2029, both dates inclusive

60% of the Share Options shall be vested from 30 April 2021 to 29 April 2029, both dates inclusive

(iii) Type 3 Share Options:

30% of the Share Options shall be vested from 30 April 2020 to 29 April 2029, both dates inclusive

30% of the Share Options shall be vested from 30 April 2021 to 29 April 2029, both dates inclusive

40% of the Share Options shall be vested from 30 April 2022 to 29 April 2029, both dates inclusive

Each of the Grantees is entitled to exercise such maximum number of Share Options granted to him/her as prescribed for that exercisable period (excluding the outstanding and unexercised Share Options granted in the preceding exercisable period, if any). Outstanding and unexercised Share Options at the end of each exercisable period shall lapse at the expiry of that exercisable period and are not allowed to be rolled over to the next exercisable period.

Each Share Option shall entitle the Grantees to subscribe for one Share upon exercise of such Share Option at an exercise price of HK\$1.44 per Share.

Among the Share Options granted, a total of 2,350,000 Share Options were granted to one executive Director and two independent non-executive Directors of the Company, details of which are as follows:

Name of Directors	Position(s) held with the Company	Number of Share Options granted	Type of Option granted
Ms. Hai Hiu Chu	executive Director	1,850,000	Type 1
Dr. Ko Wing Man	independent non-executive Director	250,000	Type 1
Mr. Wong Kon Man Jason	independent non-executive Director	250,000	Type 1

A total of 4,520,000 Type 2 Share Options and 1,130,000 Type 3 Share Options were granted to 16 and 10 of the remaining Grantees respectively.

The independent non-executive Directors of the Company (excluding independent non-executive Directors who are the Grantees of the Share Options concerned) have approved the grant of Share Options to the above Directors. Save as disclosed herein, no other Grantee is a director, chief executive or substantial shareholder of the Company, or an associate (as defined under the Listing Rules) of any of them.

By Order of the Board

Bamboos Health Care Holdings Limited

Hai Hiu Chu

Chairman

Hong Kong, 29 April 2019

As at the date of this announcement, the executive Director is Ms. Hai Hiu Chu and the independent non-executive Directors are Dr. Chan Kai Yue Jason, Ms. Chhoa Peck Lim Bella, Dr. Ko Wing Man and Mr. Wong Kon Man Jason.